Initial Hemophilia B Treatments Should Be Done in Hospitals, Researchers Suggest
The initial treatment in patients newly diagnosed with hemophilia B should definitely be done in hospital according to a study conducted by scientists in Turkey.
News
Children with Severe Von Willebrand Disease May Benefit from Treatments with Plasma Factors
Researchers reviewed the use of high-purity concentrates containing two plasma molecules that are lacking in patients with Von Willebrand disease (VWD), a hemorrhagic disorder. These products may be a good strategy for managing pediatric patients with VWD and hemophilia A (HA) who do not respond to other treatments. The study, “Human Von…
Rare New Case of Pseudotumor in non-Hemophiliac Patient Reported
Researchers at the Mayo Clinic Arizona have reported a third rare case of hemophilic pseudotumor (HP) identified in a non-hemophiliac patient. Findings from the investigation, “Hemophilic pseudotumor in a non-hemophilic patient treated with a hybrid procedure of preoperative embolization of the feeding arteries followed by surgical resection—A…
New Approach Seen to Identify Likely Carriers of Hemophilia A
Chinese researchers identified a new and simple method to identify women who may be carriers of the gene that causes hemophilia A.
Doctors Simultaneously Treat Patient’s Acquired Hemophilia A and Prostate Cancer
Researchers from San Joaquin General Hospital in California reported the case of a 66 year-old man who was successfully treated for acquired hemophilia A and prostate cancer simultaneously.
Hemophilia Review Highlights Improved Patient-reported Outcome Measures
In an article titled “Recognizing the need for personalization of hemophilia patient-reported outcomes in the prophylaxis era” published in the scientific journal Haemophilia, researchers reviewed two new tools that are used to measure patient reported outcome measures.
Type of Chromatin Seen to Stop ‘Jumping Genes’ from Doing Harm, as in Hemophilia
New research suggests that the main developmental role of heterochromatin, a form of dense DNA found in chromosomes, is to suppress virus-like DNA elements known as “jumping genes” from replicating and attaching themselves across a person’s genome, potentially destroying important genes and causing a variety of diseases, including hemophilia and cancer. The study, by University of North Carolina…
Sangamo’s Genome Editing Therapy for Hemophilia B Named ‘Orphan Drug’ by FDA
Sangamo BioSciences announced that its zinc finger nuclease (ZFN)-mediated genome editing product, SB-FIX, has received orphan drug designation from the U.S. Food and Drug Administration (FDA), speeding its development as a potential treatment for hemophilia B. Sangamo plans to initiate a Phase 1/2 clinical trial, SB-FIX-1501, in adults with this disease later…
Hemophilia Care May Be Improved by Implementation of New WFH Form
The World Federation of Hemophilia (WFH) has created a universal case report form for the collection of core data on hemophilic patients in a standardized format that will include relevant diagnosis, therapies, and outcome. Previous WFH forms provided only an overview of the number of patients and access to treatment.
Boy with Hemophilia A Undergoes Successful Stem Cell Transplant, Researchers Report
A number of clinical studies have reported that bone marrow-derived cells contribute to the production of clotting factor VIII (FVIII), the molecule linked to hemophilia A. Because the current treatment for this bleeding disorder is associated with some disadvantages and risk, hematopoietic stem cell transplant (HSCT) has become an emerging therapy approach…
Recent Posts
- The weight I carried during difficult years helped me grow stronger
- One woman’s long journey to a von Willebrand disease diagnosis
- Hemophilia patients’ bone health screening rates low at US HTCs
- Fitusiran, now Qfitlia, approved by FDA for hemophilia A, B patients
- ‘Nothing special’ is special in a life with hemophilia in the picture